non-significant increase in cough as an adverse event. Combined data from the four safety evaluation studies revealed a non-significant difference between groups (OR 1.47 , 95% CI 0.86, 2.49) for cough as an adverse event but the trend favoured the placebo arm.
Authors' conclusions
This review has significant limitations. However, our finding of uncertain efficacy of anti-histamines for chronic cough are similar to that for acute cough in children. In contrast to recommendations in adults with chronic cough, anti-histamines cannot be recommended as empirical therapy for children with chronic cough. If anti-histamines were to be trialled in these children, current data suggest a clinical response (time to response) occurs within two weeks of therapy. However the use of anti-histamines in children with nonspecific cough has to be balanced against the well known risk of adverse events especially in very young children.
P L A I N L A N G U A G E S U M M A R Y

Anti-histamines for prolonged non-specific cough in children
Children with non-specific cough are commonly treated with a variety of medications to treat the symptom of cough. The objective of this review was to evaluate the effectiveness of anti-histamines in children with prolonged cough that is not related to an underlying respiratory disease, that is, non-specific chronic cough. We included three therapeutic studies with 182 randomised participants. Two studies found that chronic cough significantly improved in both treatment and placebo groups with no difference between the two groups. One small study however described that children who had chronic cough associated with seasonal allergic rhinitis treated with cetirizine improved significantly more than children on placebo and this difference was evident by two weeks. Four studies that evaluated safety profiles included 3166 randomised participants and described a non significant increase in cough in participants who received the active medication. Despite the limitations of this review, our findings are similar to the review on anti-histamines for acute cough which showed no good evidence for or against the use of anti-histamines. In contrast to recommendations in adults with chronic cough, anti-histamines cannot be recommended as empirical therapy for children with chronic cough. Further research examining the effects of this treatment using child appropriate cough outcome measures is needed.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
anti-histamines for prolonged non-specific cough in children Patient or population: patients with prolonged non-specific cough in children Settings: Cough reported as an adverse events in safety studies Intervention: anti-histamines *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
B A C K G R O U N D
Cough is the most common symptom presenting to general practitioners (Britt 2002; Cherry 2003) and causes significant anxiety to parents (Cornford 1993) . Worldwide the desire to reduce the impact of the symptom of cough is reflected in the billions of dollars spent on over the counter cough and cold medications. Non-specific cough has been defined as non-productive cough in the absence of identifiable respiratory disease or known aetiology (Chang 2001). While some children with chronic non-specific cough have asthma, the majority do not (McKenzie 1994; Chang 1999) . In adults, chronic cough is defined as cough of over eight weeks duration but the definition commonly accepted in children is that of over three to four weeks, based on the known differences between paediatric and adult cough (Chang 2005b). 
O B J E C T I V E S
To evaluate the effectiveness of anti-histamines in treating children with prolonged non-specific cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing anti-histamines with a placebo medication with cough as an outcome, where cough is not primarily related to an underlying respiratory disorder such as cystic fibrosis, asthma, or suppurative lung disease.
Types of participants
Children with chronic (> 4 weeks) non-specific cough (dry and non-productive cough without any other respiratory symptom, sign or systemic illness). Exclusion criteria: cough related to mycoplasma, pertussis and chlamydia, presence of underlying cardio-respiratory condition, current or recurrent wheeze (> 2 episodes), presence of other respiratory symptoms (productive or wet cough (Chang 2005a) , haemoptysis, dyspnoea), presence of other respiratory signs (clubbing, chest wall deformity, respiratory noises such as wheeze on auscultation and other adventitious sounds), presence of any sign of systemic illness (failure to thrive, aspiration, neurological or developmental abnormality), presence of lung function abnormality.
Types of interventions
All randomised controlled comparisons of any type of anti-histamines. Trials only comparing two or more medications without a placebo or placebo-like medication (i.e. medications known not to improve cough) comparison group were not included. Trials that included the use of other medications or interventions were included if all participants had equal access to such medications or interventions.
Types of outcome measures
Attempts were made to obtain data on at least one of the following outcome measures:
Primary outcomes
Proportions of participants who were not cured or not substantially improved at follow up (clinical failure). 
Secondary outcomes
Search methods for identification of studies Electronic searches
The following topic search strategy was used to identify the relevant randomised controlled trials from electronic databases (see Appendix 1 for the full search strategies): ["cough" OR "bronchitis", all as (textword) or (MeSH )] AND ["histamine H 1 receptor antagonist" OR "histamine H 1 antagonist" OR "anti-histamines" OR "antazoline", OR "methapyrilene" OR "pyrilamine" OR "tripelennamine" OR "clemastine" OR "dimenhydrinate" OR "diphenhydramine", OR "doxylamine" OR "brompheniramine", OR "chlorpheniramine" OR "dimethindene", OR "pheniramine" OR "promethazine" OR "triprolidine", OR "cetirizine" OR "hydroxyzine" OR "meclizine", OR "astemizole" OR "cyproheptadine" OR "loratadine", OR "terfenadine"; ] AND ["child" OR "children" OR "pediatrics"; all as (textword) 
Searching other resources
We also consulted the list of references in relevant publications, and wrote to authors of trials included in the review.
Data collection and analysis
Selection of studies
Retrieval of studies: from the title, abstract, or descriptors, two review authors (AC, MM) independently reviewed literature searches to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, two review authors (AC, JP) independently selected trials for inclusion. Disagreement was resolved by consensus.
Data extraction and management
We reviewed trials that satisfied the inclusion criteria and recorded the following information: study setting, year of study, source of funding, patient recruitment details (including number of eligible participants), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, dose and type of intervention, duration of therapy, co-interventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intention-to-treat analyses were possible. We extracted data on the outcomes described previously. Further information was requested from the lead or corresponding author of five studies.
Assessment of risk of bias in included studies
Two review authors (AC, MM) independently assessed studies included in the review for quality assessment. Four components of quality were assessed: While only the allocation concealment quality assessment was displayed in the meta-analysis figures, all assessments were included in the 'Characteristics of included studies' table. Inter-reviewer reliability for the identification of high quality studies for each component was measured by the Kappa statistic. Quality of the studies were also assessed using Revman's 'Bias tool'.
Measures of treatment effect
For the dichotomous outcome variables of each individual study, it was planned that relative and absolute risk reductions would have been calculated using a modified intention-to-treat analysis. This analysis assumes that children not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). An initial qualitative comparison of all the individually analysed studies of all the individually analysed studies was performed to examine whether pooling of results (meta-analysis) was reasonable. This was to take into account the differences in study populations, inclusion/exclusion criteria, interventions, outcome assessment, and estimated effect size.
Unit of analysis issues
For crossover studies, mean treatment differences would have been calculated from raw data, extracted or imputed and entered as fixed-effect generic inverse variance (GIV) outcome, to provide summary weighted differences and 95% confidence intervals. In cross-over trials, only data from the first arm would have been included in meta analysis if data is combined with parallel studies (Elbourne 2002).
Data synthesis
It was planned that results from studies that met the inclusion criteria and reported any of the outcomes of interest would be included in meta-analyses. The summary weighted risk ratio and 95% confidence interval (fixed-effect model) would have been calculated (Cochrane statistical package, RevMan version 5). Numbers needed to treat (NNT) would have been calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003). The cough indices would have been assumed to be normally distributed continuous variables so the mean difference in outcomes could be estimated (mean difference). If studies reported outcomes using different measurement scales, the standardised mean difference would have been estimated. Any heterogeneity between the study results would have been described and tested to determine if it reached statistical significance using a chi-squared test. The 95% confidence interval estimated using a random-effects model would have been included whenever there were concerns about statistical heterogeneity. Statistical calculations for proportions were calculated using the CIA program (Gardner 1992) when these calculations were not provided in the papers. We have presented a Summary of Findings table based on methods recommended in the Cochrane Handbook.
Subgroup analysis and investigation of heterogeneity
An a priori sub-group analysis was planned for:
1. children aged less than seven years and seven years and above.
2. anti-histamines as monotherapy vs combination therapy 3. older anti-histamines versus new generation non sedating anti-histamines.
Sensitivity analysis
Sensitivity analyses were planned to assess the impact of the potentially important factors on the overall outcomes: a) study quality; b) study size; c) variation in the inclusion criteria; d) differences in the medications used in the intervention and comparison groups; e) differences in outcome measures; f ) analysis using random-effects model; g) analysis by "treatment received"; h) analysis by "intention-to-treat"; and i) analysis by study design-parallel and cross over studies.
Results of the search
The Airways Group specialised register/search identified 330 potentially relevant titles in the 2005 search. After assessing the abstracts, 24 papers were retrieved and 21 potential studies were considered (see 'Characteristics of excluded studies' table). The main reason for non-eligibility of studies for review criteria was the age of the participants (adult based studies). Two papers included small numbers of adolescents. No additional data could be obtained from authors and data specific to children could not be separated. Thus these papers were also excluded. Three studies were included (see 'Characteristics of included studies' table), two were single centre studies (Christensen 1971; Ciprandi 1997) and one was a multi centre study (van Asperen 1992) that was supported by commercial interest. All studies were published in full and all but one (Christensen 1971) were published in English. In the 2006 search, no new studies fulfilled inclusion criteria. Four papers were retrieved and three were added to the excluded studies table. In the 2007 search, five papers were retrieved and two of these were non-therapeutic studies but were primarily on the safety 
Included studies
All studies that were therapeutic studies included cough as a major inclusion criteria but one study (van Asperen 1992) also included children with wheeze i.e. presence of chronic cough or wheeze was an inclusion criteria. One study was in very young children (age 6 to 36 months), and two other studies were in older children (mean age 8.5 (Ciprandi 1997) and 11.5 (Christensen 1971) years). In these two studies (Christensen 1971; Ciprandi 1997) children also had allergic rhinitis. Two studies utilised parallel design ( Ciprandi 1997; van Asperen 1992) and one was a cross over study (Christensen 1971) . The safety evaluation studies were large multicentre studies performed in young children (< 6 years) with allergic rhinitis ( Outcome measures for all studies were subjective cough scales of varying types. Two studies had outcome assessments on multiple occasions (Ciprandi 1997; van Asperen 1992) and all provided cough as an outcome measure. Objective cough monitoring was not used in any study.
Risk of bias in included studies
For the therapeutic studies, the quality score varied with no study scoring 'high quality' in all four categories. One study (Ciprandi 1997) scored 'high quality' in three categories and two studies (Christensen 1971; van Asperen 1992) had high quality points for two categories. The reason for the difference between the three studies is because the latter two study had a withdrawal rate of > 10% of participants. None of the studies clearly described their method of randomisation and allocation concealment was unclear in all studies. Method of blinding (that is, appearance of placebo) was clearly described in one study (van Asperen 1992) . Agreement between the two main review authors (AC and MM) for quality of studies was excellent; weighted kappa was 0.74 for quality assessment. See 'Risk of bias' below. None of the studies described allocation method.
Effects of interventions
See: Summary of findings for the main comparison Antihistamines for prolonged non-specific cough in children The three studies with cough as inclusion criteria (that is, therapeutic studies) included 182 randomised participants with 162 completing the trials. The additional four studies that evaluated safety of the medications included 3166 randomised participants with 2862 completing the trials. The two larger therapeutic studies (Christensen 1971; van Asperen 1992) found no significant difference between treatment and placebo arms but the very small study (n = 20 in total) (Ciprandi 1997) found a significant difference between the groups. In the multicentre study (van Asperen 1992), only 13 (11%) children had chronic cough alone, the rest of the participants had cough with wheeze. The authors could not provide data specific to the cough group alone. Considering all participants, Van Asperen and colleagues reported that the "percentage of symptom free days increased significantly in both groups (P < 0.005) with placebo-treated infants experiencing more symptom-free days compared with the ketotifen group (P < 0.01)" (van Asperen 1992). Given the limitation of cough specific data, it was not possible to combine any data for meta-analysis from the therapeutic studies. In the safety evaluation studies (Milgrom 2007; Simons 2007, Meltzer 2004, Hampel 2007), cough or increased cough, was reported as an adverse event and these could be combined in a forest plot (Figure 1) . Combined data from the four safety evaluation studies revealed a non-significant difference between groups (OR 1.47 , 95% CI 0.86, 2.49) for cough as an adverse event but the trend favoured the placebo arm. These data are presented in a the Summary of findings for the main comparison. Meltzer 2004 study described significant improvement in allergy rhinitis score (cough not present in score) but with a non-significant increase in cough as an adverse event (19 of 1110 in active arm and 6 of 700 in placebo arm) in the anti-histamine arm compared to placebo. Summary of specific outcomes as reported by the therapeutic studies are as follows:
Clinical failures/success
Subjective assessment of treatment as assessed by parent(s) and by investigator was not significantly different between treatment (ketotifen) and placebo (van Asperen 1992). The proportion as reported by parents to have had good/very good efficacy was 29/ 52 in the ketotifen arm versus 26/50 in placebo arm (observed difference between proportions = 0.04, 95% CI -0.16 to 0.23). Symptom free proportions were also similar between groups on pimethixen and paradryl (34/45 versus 31/45; observed difference between proportions = 0.07, 95%CI -0.12 to 0.25) (Christensen 1971). In contrast, the study on cetirizine reported that "cetirizine's overall therapeutic effectiveness was judged satisfactory in all patients...."; data on placebo was not provided (Ciprandi 1997). Success and failures were not relevant in the safety evaluation studies. However the study on fexofenadine reported cough increased in 10 children who received fexofenadine compared to seven who received placebo. The second safety evaluation study reported four in the levocetirizine arm had cough versus two in the placebo arm. Combining these studies, there was no significant difference between groups (OR 1.6, 95% CI 0.7 to 3.82) but the trend was reduced participants with cough in the placebo arm compared to the active arms.
Mean differences in cough scores
Despite the large difference in sample size of the studies, both studies with a longer intervention period (Ciprandi 1997; van Asperen 1992) provided the mean of the group's cough score at the various time points. However, data could not be combined in a meta-analysis as data specific to children with chronic cough was not available in one study (van Asperen 1992). Authors of this study reported that day and night time cough scores significantly decreased with time with no difference between the treatment (ketotifen) and placebo groups (van Asperen 1992). In the cetirizine versus placebo study, cough scores were significantly less in the cetirizine group when compared to the placebo group (P = 0.01 for week two and three, P = 0.02 on week four) (Ciprandi 1997).The third study did not provide data on mean cough scores (Christensen 1971).
Time to response
In Ciprandi and colleagues' four week study, the difference between treatment and placebo arm was evident by the second week. The significant difference in cough frequency and cough intensity between the treatment and placebo arms remained at weeks two, three and four but there was no difference in the cough scores within each arm with further therapy (Ciprandi 1997). As the other two studies (Christensen 1971; van Asperen 1992) did not find a difference between groups, 'time to response' was not relevant in these studies.
Adverse events
Ciprandi and colleagues reported no adverse events (Ciprandi 1997). Van Asperen and colleagues reported more adverse events in the ketotifen group (57%) versus placebo (43%) (van Asperen 1992). Statistical calculation however showed that this difference was not significantly different (observed difference 0.14, 95% CI -0.05 to 0.33). Most of the events reported were minor with irritability and gastrointestinal upset being the most common events.
In four children (two each in both arms of the study), adverse events lead to withdrawal of the child from the study (van Asperen 1992). In Christensen and colleagues' study, 12 children described sedation (with three being severe) during pimethixen treatment where as 13 described mild to moderate sedation during paradryl treatment (Christensen 1971).
Sensitivity analyses
Sensitivity analysis could not be performed as data could not be combined for meta-analysis.
D I S C U S S I O N
This systematic review found seven studies that fulfilled the inclusion criteria, three were therapeutic studies and four safety evaluation studies. The review is limited by the lack of appropriate data; meta-analysis could be only be performed in the safety evaluation studies. Results from the two larger therapeutic studies (van Asperen 1992; Christensen 1971) which described no beneficial effect is in contrast to the small study (Ciprandi 1997) which showed that cetirizine, a second generation anti-histamine, was beneficial in reducing cough associated with seasonal allergic rhinitis. The combined data from the safety evaluations studies showed a non-significant difference in number of participants with cough but the direction of effect was in favour of the placebo arm. In three of these four studies, children with allergic rhinitis were enrolled.
The three included therapeutic studies were different in several ways. Firstly, some clinical heterogeneity was present in the participants of the studies; although all studies were in children with chronic cough, the participants in one study (van Asperen 1992) were very young whereas the participants in the other studies (Christensen 1971; Ciprandi 1997) were older. Secondly, all three studies used a different type of anti-histamine. Adult cohort data suggest that first generation anti-histamines are more efficacious than second generation anti-histamines in reducing While it possible that the use of this would have reduced the demonstrable effect of the anti-histamine in the study, it is more likely that the antihistamine was not efficacious; Christensen and colleagues' study (Christensen 1971) had a sample size 2.5 times that of the study (Ciprandi 1997) that found some benefit. Lastly, the studies also differed in sample size from very small (n = 20; Ciprandi 1997) to a much larger sample size (n = 113; van Asperen 1992).
Two studies reported on adverse events in both treatment and placebo groups (Christensen 1971; van Asperen 1992). When we calculated the proportions we found no significant differences between the groups. The medical literature however reports that the adverse effects of anti-histamines, in particular first generation anti-histamines, include sedation, paradoxic excitability, dizziness, 
A U T H O R S ' C O N C L U S I O N S Implications for practice
With the lack of evidence, the routine use of anti-histamines in treating children with non-specific cough cannot be recommended and is arguably contra-indicated in young children because of its side effects. If anti-histamines are to be trialled in these children, current data suggest a clinical response (time to response) occurs within two weeks of therapy. However the use of anti-histamines in children with non-specific cough has to be balanced against the well known risk of adverse events especially in very young children.
Implications for research
Randomised controlled trials of anti-histamines to determine the effectiveness in treating children with non-specific cough are clearly needed. Trials should be parallel studies and double blinded given the known problems in studying cough, specifically the large placebo and time period effects. Safety data should also be incorporated. Based on a single RCT, a short trial of two weeks would suffice. Outcome measures for the clinical studies on cough should be clearly defined using validated subjective data and supported by objective data if possible.
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Hampel 2007
Methods Safety and tolerability study of fexofenadine hydrochloride in children aged 6 months to 2 years. 
Meltzer 2004
Methods Multicentre double-blind, randomised, placebo-controlled, parallel-group, 2-wk trials. Three studies were reported within this paper. All three studies had a similar design with regard to patient selection criteria and, primary and secondary outcome measures. Following visit 1, the studies included four additional visits: visit 2, randomisation (day 1) ; visit 3, during double-blind treatment (day 6-10); visit 4, end of double-blind treatment (day15-17); and visit 5, follow-up (day 22-24).
For inclusion at visit 1, total symptom score (TSS) (see below for score details) of 6, with two or more symptoms with a minimum score of 2 (moderate), was necessary. This was followed by completion of a single-blind, placebo lead-in period, the children in study were required to have a TSS score that differed in the studies High grade score: 3 Grading: Allocation concealment= B. Blinding=A Reporting of participants by allocated group=A Follow up=A Participants Inclusion criteria: presence of seasonal allergic rhinitis (SAR) symptoms (see belowoutcomes) at entry and persisted after single-blind placebo lead-in. Children aged 6-11 years, with spring or fall SAR, and a history of SAR of approximately 1 year or more during at least one previous relevant season. Subjects were required to have a positive skin-prick test (wheal diameter of at least 3 mm than that with diluent within 15 min of the skin prick) to at least one allergen for the current season. For one of the 3 studies, presence of an allergen-specific immunoglobulin E (IgE) that was positive in the skinprick test was also required Exclusion: patients were (but were not limited to) those with a respiratory tract nasal infection, sinusitis, or otitis media within 30 days of study entry; clinically significant cardiovascular, hepatic, neurologic, psychiatric, endocrine or other major systemic disease; or immunotherapy treatment A total of 1810 children were included in the overall paediatric safety population (placebo, n=700; fexofenadine n=1110) 
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